Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Total Current Liabilities (2019 - 2026)

Kymera Therapeutics (KYMR) has disclosed Total Current Liabilities for 8 consecutive years, with $62.6 million as the latest value for Q1 2026.

  • For Q1 2026, Total Current Liabilities rose 6.19% year-over-year to $62.6 million; the TTM value through Mar 2026 reached $62.6 million, up 6.19%, while the annual FY2025 figure was $83.2 million, 22.79% up from the prior year.
  • Total Current Liabilities hit $62.6 million in Q1 2026 for Kymera Therapeutics, down from $83.2 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $91.1 million in Q3 2022 and bottomed at $54.6 million in Q2 2023.
  • Average Total Current Liabilities over 5 years is $71.8 million, with a median of $67.8 million recorded in 2024.
  • Year-over-year, Total Current Liabilities tumbled 37.6% in 2023 and then soared 40.87% in 2025.
  • Kymera Therapeutics' Total Current Liabilities stood at $71.3 million in 2022, then rose by 20.11% to $85.7 million in 2023, then dropped by 20.92% to $67.8 million in 2024, then grew by 22.79% to $83.2 million in 2025, then dropped by 24.72% to $62.6 million in 2026.
  • According to Business Quant data, Total Current Liabilities over the past three periods came in at $62.6 million, $83.2 million, and $71.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.